CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study
(2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2022). CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study. Value in Health, 25(7, Supplement), Page S305. https://doi.org/10.1016/j.jval.2022.04.105
POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis (2022)
Conference Proceeding
Robson, J., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Ndosi, M. (2022). POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis. . https://doi.org/10.1136/annrheumdis-2022-eular.1769Background Giant cell arteritis (GCA) is caused by inflammation of the blood vessels of the head and neck; patients can present with cranial, ocular or large vessel vasculitis involvement. Treatment is with glucocorticoids, steroid sparing agents a... Read More about POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis.
OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. C. (2022). OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study. Rheumatology, 61(Supplement_1), https://doi.org/10.1093/rheumatology/keac132.023
Development and validation of a patient reported outcome measure for giant cell arteritis (2021)
Presentation / Conference
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2021, November). Development and validation of a patient reported outcome measure for giant cell arteritis. Poster presented at ACR Convergence 2021, Online